Aim: To develop a combined predictive model for preterm and term pre-eclampsia (PE) during the first trimester of pregnancy. Methods: This investigation was a nested case-control study in singleton pregnancies at the Maternal-Fetal Medicine Unit, University of Chile Hospital. A priori risks for preterm and term PE were calculated by multivariate logistic regression analyses. Biophysical markers were log 10 -transformed and expressed as multiples of the median. A multivariate logistic regression analysis was used to estimate a combined predictive model of preterm and term PE. Detection rates at different cut-off points were determined by a receiver operator curve analysis of a posteriori risks. Results: First trimester mean arterial pressure and uterine artery Doppler pulsatility index were significantly higher in women who develop PE than in the unaffected group. The detection rate of preterm PE based on maternal characteristics and biophysical markers was 72% at a 10% false-positive rate, corresponding to a cut-off risk of 1 in 50. The detection rate for term PE was 30% at a 10% false-positive rate. Conclusion: Preterm PE can be predicted by a combination of maternal characteristics and biophysical markers. However, first trimester screening is less valuable for term PE.
Introduction
Pre-eclampsia (PE) is one of the main causes of maternal morbidity and mortality in developed countries. 1 In Chile, pregnancy-associated hypertension represents the second cause of maternal death, according to the last national report. 2 From a public health point of view, the development of a predictive model of PE is of major interest to establishing a universal screening program. However, the identification of a high-risk population needs a low-cost preventive strategy to be cost-effective.
Thus far, several meta-analyses and a recent randomized controlled trial have proven that high-risk populations could benefit from the use of aspirin started before 16 weeks of gestation. [3] [4] [5] [6] Although the performance of a screening test for PE in the second trimester of pregnancy is the best approach, 7 an earlier assessment might ensure a reduction in the risk of PE in women who develop this condition. In this vein, several first trimester predictive models have been published, requiring a combination of maternal history, biochemical markers and uterine artery Doppler (UtAD). 5, [8] [9] [10] [11] [12] [13] At a fixed false-positive rate of 10%, the detection rates (DR) vary, depending on the population, from 47% to 96%. 8, 14 Interestingly, the incorporation of the mean arterial pressure (MAP) at the first trimester screening has been demonstrated to improve the DR of these models. The aim of this study was to develop a first trimester combined predictive model for preterm and term PE that includes maternal history and biophysical markers.
Methods

Study design
This was a nested case-control study within an ongoing 11 + 0 to 13 + 6 weeks screening program at the Fetal Medicine Unit, University of Chile Hospital, from November 2010 to January 2017. At the appointment, all patients were offered a risk assessment for PE and chromosomal abnormalities that included maternal characteristics, medical and obstetrics history and an assessment of MAP and transvaginal UtAD. Gestational age was calculated by crown-torump length (CRL) in all pregnancies. 15 Perinatal outcomes were obtained from the labor and delivery unit or by phone contact with patients who delivered in another institution. This study was approved by the local Ethics Committee of Hospital Clínico de la Universidad de Chile (Registry No. 57) and was funded by Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) (Registry No. 1130668).
Patient selection
For this study, only singleton pregnancies with a complete screening and known perinatal outcome were included. Patients with spontaneous abortion before 22 weeks of gestation, the presence of aneuploidy diagnosed prenatally or after delivery or a major birth defect were excluded from the analysis. Genetic syndromes diagnosed after birth were also excluded. All patients who agreed to participate signed a written informed consent.
Definitions
For this study, PE was defined as hypertension developing after 20 weeks of gestation and proteinuria ≥300 mg/day (or spot urine protein/creatinine ratio ≥30 mg/mmol or dipstick 2+) in a previously normotensive patient, according to the revised statement of the International Society for the Study of Hypertension in Pregnancy. 16 Preterm PE (p-PE) and term PE (t-PE) were defined as individuals with PE who delivered before and after 37 weeks of gestation, respectively.
Small for gestational age (SGA) was defined as a birthweight <10th percentile, according to local standards. 17 Fetal growth restriction (FGR) was defined as SGA with altered Doppler, SGA delivered before 37 weeks of gestation due to fetal or maternal condition, or a birthweight less than 3rd percentile, irrespective of Doppler status or gestational age at birth. 18 
Maternal characteristics
All pregnant women were asked to complete an oral questionnaire, which was stored in our Astraia (r) database. The maternal characteristics included were maternal age, mode of conception (spontaneous or assisted reproductive technology), maternal height, maternal weight before pregnancy and at ultrasound, body mass index (BMI), ethnicity, smoking habit (yes or no), previous PE (yes or no), previous SGA newborn (yes or no), birthweight of previous pregnancy, previous spontaneous preterm delivery (yes or no) and background of chronic diseases, including the following: chronic hypertension (chrHT) (yes or no), autoimmune diseases (yes or no) and diabetes mellitus 1 or 2 (yes or no).
Biophysical markers
Blood pressure was assessed twice in both arms in all patients, according to the Seventh Joint National Committee (JNC-7) recommendations 19 using an automatic validated tensiometer (OMRON HEM-7113, Omron Healthcare Inc.). MAP was calculated as follows: MAP = DBP + (SBP-DBP)/3, with MAP as the mean arterial pressure, DBP as the diastolic blood pressure and SBP as the systolic blood pressure.
The transvaginal UtAD was measured using an Accuvix A30 (Samsung Medison) or Aloka 4000 (Aloka) machine with a 5-8 MHz endo-cavitary probe. The technique used was as follows: Patients were placed in lithotomy position, and the transducer was introduced into the vagina and placed at the anterior fornix. After identification of the cervix, the transducer was tilted laterally, at the level of the internal os. Color Doppler was used to identify left and right uterine arteries. Pulsed Doppler was used after confirmation of an insonation angle <30
. When three consecutive similar waves were obtained, the image was stored, and the pulsatility index (PI) was calculated. 20 The mean PI of the left and right UtAD was calculated and stored.
Study outcomes
The primary outcome was the diagnosis of p-PE with or without FGR. The secondary outcome was the diagnosis of t-PE.
Statistical analysis
All statistical analyses were performed with STATA v14.2 software (Statacorp). For continuous variables, Student's t-test or the Mann-Whitney U test was used and expressed as the mean (standard deviation) or median (interquartile range [IQR]) for parametric and nonparametric distributions, respectively. Categorical variables were compared with Pearson's chi-square test and expressed as n (%). For the analysis of predictive variables, a Bayes theorem approach was used.
A priori risk
First, maternal characteristics were explored with a univariate logistic regression analysis to determine the odds ratios (OR) of variables significantly associated with the primary outcome. Second, a multivariate logistic regression analysis was applied, using a backward stepwise elimination method. Variables with a P value less than 0.05 were retained in the final model. Finally, to determine the individual risk, odds were calculated as follows: Odds = e y . Then, risk was estimated as follows: Odds/(1 + Odds). The a priori risk was log 10 -transformed before including in the a posteriori risk model.
Biophysical predictor markers
First, MAP and UtAD were log 10 -transformed to make their distribution Gaussian. Second, a multivariate linear regression was performed to identify which variables were significant predictors of log 10 MAP and log 10 UtAD in the unaffected group. The obtained regression was used to determine multiples of the median (MoM) of both markers. For missing values of UtAD measurements in 14 controls, a multiple imputation analysis of missing values was performed.
A posteriori risk
To determine the a posteriori risk, a multivariate logistic regression was applied, combining the a priori risk (log10) , MoM-MAP and MoM-UtAD. A receiver operator curve analysis was performed to determine the DR at a fixed false-positive rate of 10%. The obtained regression formula was used to determine the individual risk, in the same manner as a priori risk estimation. Finally, the DR at different a posteriori risk cut-offs was estimated.
For group comparison, a P value less than 0.05 was considered significant.
Results
During the study period, we included 1812 patients. Of these, 56 were excluded for spontaneous miscarriage (30), stillbirth (8) , neonatal death related to major congenital defect (4) and live birth with a major congenital defect (14) . After exclusion, 1756 singleton pregnancies were included in the final analysis. Fortynine (2.8%) patients developed PE, and 29 of them were delivered before 37 weeks of gestation. Maternal characteristics and the obstetric history of the study population are presented in Table 1 . Patients who subsequently developed PE were older and heavier and had higher rates of smoking and chrHT than patients with unaffected pregnancies. There were no differences in ethnicity, with a predominance of the white Hispanic population in both groups. Twentynine percent of patients in the PE group had a history of PE in a previous pregnancy, compared to 2.5% of patients in the unaffected group (P < 0.0001).
At screening, pregnancies that developed PE presented a significantly higher SBP and DBP, with a MAP of 85 mmHg (78.8-93.3) and 80 mmHg (73.3-86.3) in the PE and unaffected groups, respectively ( Table 2 ). The mean UtAD was also higher in the PE group, with an almost threefold higher rate of pregnancies with a PI above the 90th percentile. Perinatal outcomes are presented in Table 2 .
A priori risk
A univariate logistic regression model was performed to identify the maternal characteristic risk factors for p-PE and t-PE. Regarding p-PE risk factors, chrHT (OR = 13), systemic lupus erythematosus (SLE) (OR = 8), previous history of PE (OR = 27), SGA (OR = 12) and spontaneous preterm delivery (OR = 8) presented higher risk. However, after a multivariate analysis, only chrHT, SLE and a previous history of PE were retained in the model (Table 3) . For t-PE, only BMI and smoking habit were associated with a modest but significantly higher risk.
The a priori risk for p-PE was obtained with the following formula: 
Biophysical markers
In the unaffected group, MAP log10 was better predicted with the following formula: In addition, in the unaffected pregnancies, the mean UtAD PI log10 was better predicted with the following formula: As presented in Figure 2 , first trimester MoM-MAP and MoM-UtAD were inversely and significantly correlated with gestational age at delivery (r = −0.1016; P < 0.0001 and r = −0.1377; P < 0.0001, respectively, for global PE). With regard to t-PE, at a fixed false-positive rate of 10%, the DR based on a priori risk log10 was 30.0% (AUC: 0.690 [0.580-0.799]). However, both MoM-MAP and MoM-UtAD were not significantly associated with t-PE and were therefore not included in the final model. Table 4 shows the DR and false-positive rates of different a posteriori risk cut-offs for p-PE. At a cut-off risk of 1 in 100, 27.2% of pregnancies were classified as high-risk but with a 25.7% false-positive rate. To reduce the false-positive rate without significantly affecting the DR, a cut-off risk of 1 in 50 might be considered more appropriate for our population, due to the fact that only 7.8% were classified as high-risk pregnancies with a 72% DR and only a 10.4% false-positive rate. 
Combined predictive model for PE
Discussion Main findings
This study corroborates that a first trimester predictive model of PE that combines maternal characteristics and biophysical markers, such as MAP and UtAD, can detect a high proportion of pregnancies destined to develop PE before 37 weeks of gestation, with a 10% false-positive rate. However, the DR of t-PE appears to be poorer at this gestational age, and particularly, the biophysical markers were not associated with this subtype of PE.
Strengths and limitations
To our knowledge, the main strength of our study was being the first predictive model for p-PE developed in a Latin American population at the 11 + 0 to 13 + 6 weeks scan, which combines maternal characteristics with adjusted biophysical markers in a clinical setting. An algorithm was provided to compare our model with already validated models applied in a clinical setting in our population. Second, the use of a validated and well-described methodology for the adjustment of biophysical markers, expressed as MoM, allows our results to be compared with those of other publications. Additionally, the use of a Bayesian theorem approach for a priori and a posteriori risk estimation allows for an individualized assessment and management, based on predefined cut-off points. Finally, the use of a clinical and research-dedicated database, with a prospective collection of perinatal outcomes, ensures the quality of our data. However, this study is not without limitations. First, we did not evaluate any angiogenic/anti-angiogenic marker in maternal plasma, such as placental growth factor (PLGF) or pregnancy-associated protein plasma A. Therefore, the real impact of these markers in our population is unknown, despite a good DR with the present model, similar to other publications. 11, 21 Second, we acknowledge that this study was performed in a tertiary center by experts with major experience in first trimester ultrasound, affecting the external validations of our results. In this vein, the need to validate this model and compare its performance with a more robust already published model, such as the Fetal Medicine Foundation algorithm 21 appears to be mandatory in the near future. Third, considering that the use of aspirin from the first trimester could affect the results of our model, we did not have data in all patients regarding this use. Therefore, a statistical adjustment was not feasible to perform. Finally, it is important to consider that the high false-positive rate for different cut-offs that we described might be influenced by our particular ethnicity, which is a mixture of nativeAmerican and European population 22 and by the possible use of aspirin and lack of adequate adjustment.
Interpretation
The high DR of p-PE based on a priori risk (62.1%) could be explained by local population characteristics, where 3.8% of the screened population have a background of chronic hypertension, and 5.9% of parous females have developed PE in a previous pregnancy. However, Wright D et al. described that in parous patients, a priori risk detected 61.7% of p-PE at a 10% false-positive rate, which is similar to our findings.
11
Regarding the performance of combined models, in a recent study, O'Gorman et al. screened 35 948 singleton pregnancies at 11 + 0 to 13 + 6 weeks. They demonstrated that by combining maternal characteristics, MoM-UtAD and MoM-MAP, the DR of p-PE was 70% (95% confidence interval 64-75) at a 10% fixed false-positive rate. 21 The inclusion of PLGF into the predictive model marginally improved the DR to 75%. Moreover, our group published that adding PLGF into a predictive model can only increase the DR in our population by three percentile points. 14 Based on these findings and the eventual increase in the cost by including biochemical markers in the universal screening in our population, we believe that a model that includes maternal characteristics and biophysical markers has enough strength to detect the vast majority of women who will benefit from taking aspirin before 16 weeks of gestation.
Finally, from a clinical perspective, the algorithm developed by the Fetal Medicine Foundation in a randomized controlled trial demonstrated a 62% reduction of p-PE when 150 mg of aspirin was started at 11-14 weeks. 5 However, a subanalysis demonstrated that this benefit is not observed in chronically hypertensive patients. 23 In the abovementioned randomized study, a cut-off risk of 1 in 100 was considered the inclusion criteria, with values associated with a 10% screen-positive rate. However, if a similar cut-off point is used, more than 20% of our population should be classified using the screen-positive rate, which might reflect an inadequate overuse of aspirin. Therefore, a cut-off risk of 1 in 50 should be more suitable in our screening program to obtain a screenpositive rate of approximately 10%.
In conclusion, we demonstrated that the use of a first trimester model for the prediction of p-PE developed with a local population, could obtain similar DR than international reports. However, t-PE might be unlikely to be predicted properly during the first trimester of pregnancy. Local risk cut-offs should be selected before the implementation of preventive strategies in a high-risk group.
